PTPRC and acute myeloid leukemia: A Y90 conjugated-rat-derived anti-CD 45 Ig G2a monoclonal antibody, YAML568, showed good tolerability in a phase 1 study [122], and there is an ongoing phase 1 study of 90Y-DOTA BC8, an anti-CD45 antibody followed by allogenic stem cell transplantation for high-risk AML or MDS.